123 related articles for article (PubMed ID: 1424516)
1. Lack of predictability of cefotetan in vitro susceptibility tests against cefotetan-resistant anaerobic bacteria in determining clinical and bacteriologic efficacies.
Sheikh W; Bobey DG
Diagn Microbiol Infect Dis; 1992; 15(7):595-600. PubMed ID: 1424516
[TBL] [Abstract][Full Text] [Related]
2. Criteria for in vitro susceptibility testing of cefotetan. Correlations with clinical and bacteriologic responses.
Barry AL
Am J Surg; 1988 May; 155(5A):24-9. PubMed ID: 3287965
[TBL] [Abstract][Full Text] [Related]
3. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis.
Goldstein EJ; Citron DM; Merriam CV; Abramson MA
Surg Infect (Larchmt); 2009 Apr; 10(2):111-8. PubMed ID: 19226203
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of cefoxitin vs. cefotetan against clinical isolates of Bacteroides and Prevotella species.
Grossmeyer TJ; Farmer SG
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S353-6. PubMed ID: 8324146
[No Abstract] [Full Text] [Related]
5. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
Cruciani M; Navarra A; Bono L; Concia E
Chemioterapia; 1988 Aug; 7(4):261-3. PubMed ID: 3180306
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Jun; 6(2 Suppl):92-3. PubMed ID: 3509542
[No Abstract] [Full Text] [Related]
7. [Incidence of cefotetan sensitivity in anaerobic microbes responsible for acute and chronic relapsing bronchopneumonia].
Guarino C; Cautiero V; Tarantino C; Cuccurullo S; Cione B; Marcatili A
G Ital Chemioter; 1989; 36(1-3):53-6. PubMed ID: 2488913
[TBL] [Abstract][Full Text] [Related]
8. [Cefotetan treatment of suppurative bronchopulmonary syndromes sustained by anaerobic germs].
Caputi M; Guarino C; Cautiero V; Sorrentino L; Cione P; Cuccurullo S; Tarantino C
Arch Monaldi Mal Torace; 1990; 45(5):401-10. PubMed ID: 2152338
[TBL] [Abstract][Full Text] [Related]
9. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
Cruciani M; Navarra A; Bono L; Concia E
J Chemother; 1989 Jul; 1(4 Suppl):101-2. PubMed ID: 16312323
[No Abstract] [Full Text] [Related]
10. Quality control guidelines for testing cefotetan in the reference agar dilution procedure for susceptibility testing of anaerobic bacteria.
Zabransky RJ; Bobey DG; Barry AL; Allen SD; Fuchs PC; Gerlach EH; Thornsberry C; Sheikh W; Jones RN
J Clin Microbiol; 1989 Jan; 27(1):190-1. PubMed ID: 2643621
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species.
Byun JH; Kim M; Lee Y; Lee K; Chong Y
Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
[TBL] [Abstract][Full Text] [Related]
13. The comparative in-vitro activity of cefotetan against anaerobic bacteria.
Watt B; Brown FV
J Antimicrob Chemother; 1985 Jun; 15(6):671-7. PubMed ID: 3861604
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of clinically isolated anaerobic bacteria in a University Hospital Centre Split, Croatia in 2013.
Novak A; Rubic Z; Dogas V; Goic-Barisic I; Radic M; Tonkic M
Anaerobe; 2015 Feb; 31():31-6. PubMed ID: 25479237
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
Shore KP; Pottumarthy S; Morris AJ
N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
[TBL] [Abstract][Full Text] [Related]
16. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of faropenem activity against anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Bryskier A
J Chemother; 2005 Feb; 17(1):36-45. PubMed ID: 15828442
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of cefotetan plus netilmicin in the treatment of bacterial peritonitis.
Puleo S; Sammartino R; Gismondo MR; Tempera G; Nicoletti G; Latteri F; Rodolico G
Chemioterapia; 1987 Jun; 6(2 Suppl):470-1. PubMed ID: 3509474
[No Abstract] [Full Text] [Related]
20. Antimicrobial susceptibility of anaerobic bacteria in Australia.
Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
